Combination of AT-101/cisplatin overcomes chemoresistance by inducing apoptosis and modulating epigenetics in human ovarian cancer cells

Molecular Biology Reports

Volumn 40, Issue 6, 2013, Pages 3925-3933

  Karaca, Burcak ^a   Atmaca, Harika ^b   Bozkurt, Emir ^b   Kisim, Asli ^b   Uzunoglu, Selim ^b   Karabulut, Bülent ^a   Sezgin, Canfeza ^a   Sanli, Ulus Ali ^a   Uslu, Ruchan ^a  

^a EGE UNIVERSITY   (Turkey)

^b CELAL BAYAR UNIVERSITY   (Turkey)

Author keywords

Apoptosis; AT 101; Cisplatin; Epigenetics; Ovarian cancer cells

Indexed keywords

CASPASE 3; CASPASE 7; CELL DNA; CISPLATIN; CLUSTERIN; CYTOCHROME C; DEATH RECEPTOR 5; DNA METHYLTRANSFERASE 1; FAS ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; HEAT SHOCK PROTEIN 27; HISTONE DEACETYLASE 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INHIBITOR OF APOPTOSIS PROTEIN 1; ISOSORBIDE; MESSENGER RNA; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; PROTEIN P53; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; TUMOR NECROSIS FACTOR RECEPTOR 1; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL STRAIN; CELL STRAIN MDAH 2774; CELL STRAIN OVCAR 3; CELL VIABILITY; CHEMOSENSITIZATION; CONTROLLED STUDY; DNA FRAGMENTATION; DNMT1 GENE; DRUG CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; EPIGENETICS; HDAC1 GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; OVARY CANCER; PROTEIN CLEAVAGE; PROTEIN EXPRESSION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CASPASE 3; CASPASE 7; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA FRAGMENTATION; DNA METHYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; EPIGENESIS, GENETIC; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GOSSYPOL; HISTONE DEACETYLASES; HUMANS; OVARIAN NEOPLASMS;

EID: 84877747126     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-012-2469-z     Document Type: Article

References (35)

1. Herzog TJ, Sill MW, Walker JL et al (2011) A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q). Gynecol Oncol 120:454-458
2. Rakowski JA, Ahmad S, Holloway RW (2012) Use of pegylated liposomal doxorubicin in the management of platinum-sensitive recurrent ovarian cancer: current concepts. Expert Rev Anticancer Ther 12:31-40
3. Dear RF, Gao B, Harnett P (2010) Recurrent ovarian cancer: treatment with pegylated liposomal doxorubicin; a Westmead Cancer Care Centre experience. Asia Pac J Clin Oncol 6:66-73
4. Broxterman HJ, Gotink KJ, Verheul HM (2009) Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib. Drug Resist Updat 12:114-126
5. Luqmani YA (2005) Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract 14(Suppl 1):35-48
6. Balch C, Huang TH, Brown R et al (2004) The epigenetics of ovarian cancer drug resistance and resensitization. Am J Obstet Gynecol 191:1552-1572
7. Reed JC (2006) Drug insight: cancer therapy strategies based on restoration of endogenous cell death mechanisms. Nat Clin Pract Oncol 3:388-398
8. Galluzzi L, Senovilla L, Vitale I et al (2012) Molecular mechanisms of cisplatin resistance. Oncogene 31:1869-1883
9. Zerp SF, Stoter R, Kuipers G et al (2009) AT-101, a small molecule inhibitor of anti-apoptotic Bcl-2 family members, activates the SAPK/JNK pathway and enhances radiation-induced apoptosis. Radiat Oncol 4:47
10. Bauer JA, Trask DK, Kumar B et al (2005) Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL. Mol Cancer Ther 4:1096-1104
11. Kisim A, Atmaca H, Cakar B et al (2012) Pretreatment with AT-101 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of breast cancer cells by inducing death receptors 4 and 5 protein levels. J Cancer Res Clin Oncol 138:1155-1163
12. Zeller C, Brown R (2010) Therapeutic modulation of epigenetic drivers of drug resistance in ovarian cancer. Ther Adv Med Oncol 2:319-329
13. Asadollahi R, Hyde CA, Zhong XY (2010) Epigenetics of ovarian cancer: from the lab to the clinic. Gynecol Oncol 118:81-87
14. Hamilton TC, Young RC, McKoy WM et al (1983) Characterization of a human ovarian carcinoma cell line (NIH: OVCAR-3) with androgen and estrogen receptors. Cancer Res 43:5379-5388
15. Erten C, Karaca B, Kucukzeybek Y et al (2009) Regulation of growth factors in hormone- and drug-resistant prostate cancer cells by synergistic combination of docetaxel and octreotide. BJU Int 104:107-114
16. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs on enzyme inhibitors. Adv Enzyme Regul 22:27-55
17. Lin YG, Kunnumakkara AB, Nair A et al (2007) Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res 13:3423-3430
18. Atmaca H, Gorumlu G, Karaca B et al (2009) Combined gossypol and zoledronic acid treatment results in synergistic induction of cell death and regulates angiogenic molecules in ovarian cancer cells. Eur Cytokine Netw 20:121-130
19. Sanli UA, Gorumlu G, Erten C et al (2009) Targeting apoptosis in the hormone- and drug-resistant prostate cancer cell line, DU-145, by gossypol/zoledronic acid combination. Cell Biol Int 33:1165-1172
20. Cengiz E, Karaca B, Kucukzeybek Y et al (2010) Overcoming drug resistance in hormone- and drug-refractory prostate cancer cell line, PC-3 by docetaxel and gossypol combination. Mol Biol Rep 37:1269-1277
21. Hu W, Wang F, Tang J et al (2012) Proapoptotic protein Smac mediates apoptosis in cisplatin-resistant ovarian cancer cells when treated with the anti-tumor agent AT101. J Biol Chem 287:68-80
22. Moretti L, Li B, Kim KW et al (2010) AT-101, a Pan-Bcl-2 inhibitor, leads to radiosensitization of non-small cell lung cancer. J Thorac Oncol 5:680-687
23. Liu G, Kelly WK, Wilding G et al (2009) An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin Cancer Res 15:3172-3176
24. Ready N, Karaseva NA, Orlov SV et al (2011) Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer. J Thorac Oncol 6:781-785
25. Heist RS, Fain J, Chinnasami B et al (2010) Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer. J Thorac Oncol 5:1637-1643
26. Nie C, Tian C, Zhao L et al (2008) Cysteine 62 of Bax is critical for its conformational activation and its proapoptotic activity in response to H2O2-induced apoptosis. J Biol Chem 283:15359-15369
27. Mohan J, Gandhi AA, Bhavya BC et al (2006) Caspase-2 triggers Bax-Bak-dependent and -independent cell death in colon cancer cells treated with resveratrol. J Biol Chem 281:17599-17611
28. Eliopoulos AG, Kerr DJ, Herrod J et al (1995) The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and bcl-2. Oncogene 11:1217-1228
29. Daveraux QL, Takahashi R, Saivesen QS et al (1997) X-linked IAP is a direct inhibitor of cell-death proteases. Nature 388:300-303
30. Roy N, Deveraux QL, Takahashi R et al (1997) The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J 16:6914-6925
31. Liu HF, Hsiao PW, Chao C (2008) Celecoxib induces p53-PUMA pathway for apoptosis in human colorectal cancer cells. Chem Biol Interact 176:48-57
32. Li R, Hannon GJ, Beach D, Stillman B (1996) Subcellular distribution of p21 and PCNA in normal and repair-deficient cells following DNA damage. Curr Biol 6:189-199
33. Stangelberger A, Schally AV, Rick FG et al (2012) Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins. Prostate 72:555-565
34. Balch C, Fang F, Matei DE et al (2009) Minireview: epigenetic changes in ovarian cancer. Endocrinology 150:4003-4011
35. Glasspool RM, Teodoridis JM, Brown R (2006) Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer 94:1087-1092